The estimated Net Worth of Ashleigh Palmer is at least 68.8 百万$ dollars as of 10 February 2023. Mr. Palmer owns over 75,835 units of Provention Bio stock worth over 64,845,207$ and over the last 5 years he sold PRVB stock worth over 0$. In addition, he makes 3,959,460$ as President、 Chief Executive Officer、 Co-Founder、 Director at Provention Bio.
Sign up
Mr. Palmer PRVB stock SEC Form 4 insiders trading
Ashleigh has made over 9 trades of the Provention Bio stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 75,835 units of PRVB stock worth 189,588$ on 10 February 2023.
The largest trade he's ever made was exercising 75,835 units of Provention Bio stock on 10 February 2023 worth over 189,588$. On average, Ashleigh trades about 7,454 units every 78 days since 2019. As of 10 February 2023 he still owns at least 2,595,885 units of Provention Bio stock.
You can see the complete history of Mr. Palmer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ashleigh Palmer biography
Ashleigh Palmer serves as President, Chief Executive Officer, Co-Founder, Director of the Company. Mr. Palmer is a co-founder of Provention and has served as our President and CEO and on the board of directors since inception in 2016. Mr. Palmer currently serves as a non-executive director on the board of Third Pole, a clinical-stage biopharmaceutical company developing electric generated inhaled nitric oxide for certain life-threatening and debilitating critical care and chronic cardiopulmonary conditions. Mr. Palmer is also President of Creative BioVentures™ Corp. (CBV), a strategic advisory firm serving the biopharma industry. Since founding CBV in 2002, Mr. Palmer has advised numerous clients regarding corporate positioning and strategy, fund raising, merger and acquisition transactions, clinical development and commercialization, and has undertaken a number of CEO and board level transformational leadership and turnaround assignments for both public and private biopharma companies. From 2015 through 2017, Mr. Palmer served as Executive Chairman of Celimmune, LLC, a clinical development-stage immunotherapy company dedicated to developing therapies for celiac disease and refractory celiac disease. Celimmune was acquired by Amgen Inc. in November 2017. Mr. Palmer served as Chief Executive Officer of Unigene Laboratories, Inc., a biopharmaceutical company, from 2010 to July 2013 in conjunction with a substantial restructuring of Unigene’s debt. Following the debtholder’s acquisition of substantially all of Unigene’s assets, Unigene filed for bankruptcy in July 2013. Prior to founding Celimmune and CBV, Mr. Palmer was Vice President, Business Development for British Oxygen’s Ohmeda Pharmaceutical Products, Inc., where he was instrumental in its sale to a consortium led by Baxter International Inc. by spinning out the company’s inhaled nitric oxide assets as INO Therapeutics, Inc. (now Ikaria/Mallinckrodt).
What is the salary of Ashleigh Palmer?
As the President、 Chief Executive Officer、 Co-Founder、 Director of Provention Bio, the total compensation of Ashleigh Palmer at Provention Bio is 3,959,460$. There are no executives at Provention Bio getting paid more.
How old is Ashleigh Palmer?
Ashleigh Palmer is 57, he's been the President、 Chief Executive Officer、 Co-Founder、 Director of Provention Bio since 2016. There are 8 older and 9 younger executives at Provention Bio. The oldest executive at Provention Bio, Inc. is Avery Catlin, 72, who is the Independent Director.
What's Ashleigh Palmer's mailing address?
Ashleigh's mailing address filed with the SEC is C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK, NJ, 07701.
Insiders trading at Provention Bio
Over the last 6 years, insiders at Provention Bio have traded over 81,606,241$ worth of Provention Bio stock and bought 165,475 units worth 1,543,065$ . The most active insiders traders include Capital (Master), L.P.Sessa...、Nancy Wysenski、Avery W Catlin. On average, Provention Bio executives and independent directors trade stock every 35 days with the average trade being worth of 3,621,900$. The most recent stock trade was executed by Capital (Master), L.P.Sessa... on 14 April 2023, trading 2,190,549 units of PRVB stock currently worth 53,274,152$.
What does Provention Bio do?
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
What does Provention Bio's logo look like?
Complete history of Mr. Palmer stock trades at Provention Bio
Provention Bio executives and stock owners
Provention Bio executives and other stock owners filed with the SEC include:
-
Ashleigh Palmer,
President, Chief Executive Officer, Co-Founder, Director -
Eleanor Ramos,
Chief Medical Officer -
Francisco Leon,
Co-Founder, Chief Scientific Officer -
Andrew Drechsler,
Chief Financial Officer -
Ashleigh W. Palmer B.Sc., M.B.A.,
Co-Founder, Pres, CEO & Director -
Sean Doherty,
Independent Director -
Dr. Eleanor L. Ramos,
Chief Medical Officer -
Dr. Francisco Leon M.D., Ph.D.,
Co-Founder & Chief Scientific Officer -
Jason Hoitt,
Chief Commercial Officer -
Andrew T. Drechsler,
Special Advisor -
Francisco Leon M.D., Ph.D.,
Co-Founder & Chief Scientific Officer -
Jeffrey Bluestone,
Director -
Wayne Pisano,
Independent Chairman of the Board -
Avery Catlin,
Independent Director -
Sam Martin,
Investor Relations -
Nancy Wysenski,
Director -
John Jenkins,
Director -
Heidy King-Jones,
Chief Legal Officer -
Jason Hoitt,
Chief Commercial Officer -
Robert A. Doody Jr.,
VP of Investor Relations -
Christina Yi,
Chief Operations Officer -
Thierry Chauche,
Chief Financial Officer -
Dr. Sherron Kell,
Sr. VP of Clinical Devel. -
Heidy Abreu King-Jones J.D., L.L.M.,
Chief Legal Officer -
Justin Vogel,
Chief Accounting Officer -
Anthony Digiandomenico,
Director -
Miyoko Christina Yi,
Chief Operations Officer -
Benedict Osorio,
Chief Quality Officer -
Thierry Chauche,
Chief Financial Officer -
Rita Jain,
Director -
Sarah O'brien,
Chief People Officer -
Capital (Master), L.P.Sessa...,